Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response

Leonardo Baiocchi, Francesco De Leonardis, Marco Delle Monache, Lorenzo Nosotti, Renato L. Conti, Ilaria Lenci, Marco Carbone, Daniele Di Paolo, Silvia Cucchiarelli, Mario Angelico

Research output: Contribution to journalArticlepeer-review

Abstract

Background: On-treatment predictors during antiviral therapy of HCV are useful because they allow discontinuation of an unnecessary treatment in non-responders. Our aim was to evaluate the usefulness of plasma and erythrocyte ribavirin levels in predicting sustained virological response (SVR) in HCV genotype 1 patients undergoing antiviral treatment. Methods: A total of 40 HCV genotype 1 patients treated with pegylated interferon-α2a 180 μg weekly plus ribavirin 1,000 or 1,200 mg daily (according to body weight) were included in the study. Plasma and erythrocyte ribavirin levels were evaluated in all patients at week 12 by HPLC. At week 24, ribavirin levels were reassessed in those achieving early virological response (EVR). Results: A total of 27 patients achieved EVR, whereas 17 achieved SVR. There was no difference among EVR and non-EVR patients in terms of plasma and erythrocyte ribavirin concentrations at week 12. At week 24, EVR patients obtaining SVR exhibited higher mean ±SD levels of ribavirin in plasma and lower levels in erythrocytes compared with non-SVR patients (in plasma 12.8 ±10 versus 5.8 ±4 μM [P

Original languageEnglish
Pages (from-to)633-639
Number of pages7
JournalAntiviral Therapy
Volume15
Issue number4
DOIs
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Fingerprint Dive into the research topics of 'Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response'. Together they form a unique fingerprint.

Cite this